Kidney fibrosis is the buildup of scar tissue inside the kidneys, and it represents the final common pathway of virtually every form of chronic kidney disease regardless of the original cause. The scarring replaces healthy, functional tissue with a dense web of structural proteins that the kidney cannot use, progressively strangling the organ’s ability to filter blood. Because fibrosis develops silently over months or years, most people have no idea it is happening until kidney function has already declined substantially. Understanding what drives the process, how it is detected, and what can be done about it matters for anyone living with or at risk for chronic kidney disease.
What Actually Happens Inside a Fibrotic Kidney
Healthy kidneys maintain a careful balance between building and breaking down the scaffolding proteins that hold tissue together. In fibrosis, that balance tips toward overproduction. The kidney accumulates excessive amounts of extracellular matrix, the mesh of collagen and other structural proteins that normally supports cells. This buildup disrupts the cellular organization and function of the kidney, essentially burying the tiny filtering units (nephrons) under layers of scar material they cannot work through.1PubMed Central. Cell-Matrix Interactions in Renal Fibrosis Whether the original injury hit the filtering tufts (glomeruli) or the tubes and surrounding tissue (tubulointerstitium), the end result looks remarkably similar: excessive matrix deposition and a kidney that is slowly hardening and shrinking.2PubMed Central. Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold
The cells most responsible for laying down this scar are called myofibroblasts, and figuring out where they come from has been one of the more debated questions in kidney research. Older theories suggested that the kidney’s own tube-lining cells could transform into scar-producing cells through a process called epithelial-to-mesenchymal transition, but strong evidence for that actually happening inside a living kidney has been hard to find.3PubMed Central. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? More recent high-resolution mapping of human kidneys points to resident fibroblasts and pericytes (cells that wrap around small blood vessels) as the main sources of myofibroblasts during fibrosis.4Nature. Decoding myofibroblast origins in human kidney fibrosis A 2025 lineage-tracing study reinforced this view, finding that resident fibroblasts were the primary source and that transformation from other cell types contributed little.5Nature Communications. Tracing the origin of myofibroblasts in kidney fibrosis
The Major Causes and Triggers
Almost any sustained injury to the kidneys can eventually produce fibrosis. Two conditions stand out as the most common triggers worldwide: diabetes and high blood pressure.
In diabetic kidney disease, chronic high blood sugar, oxidative stress, and inflammatory signaling work together to drive excessive matrix production. Fibrosis in this setting tends to affect both the glomeruli and the surrounding tissue, and it is widely considered a late-stage change that is difficult to reverse once established.6PubMed Central. Signaling Pathways Involved in Diabetic Renal Fibrosis The overproduction and accumulation of matrix proteins leads to glomerulosclerosis and tubulointerstitial fibrosis, both of which push the kidney toward failure.7Cytokine & Growth Factor Reviews. Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression
Hypertension damages the kidneys through a different but overlapping route. Long-term high blood pressure overactivates the renin-angiotensin-aldosterone system (RAAS), which ramps up production of reactive oxygen species. Those oxygen radicals trigger inflammation, and the inflammation in turn activates fibrotic pathways. Researchers have described this as a self-reinforcing loop.8PubMed Central. The core mechanism of hypertension-linked renal fibrosis: “RAAS-ROS-inflammation-fibrosis” axis Proteinuria, tubular swelling, and chronic inflammation all contribute to the scarring process in hypertensive kidneys.9PubMed. Current Opinion for Hypertension in Renal Fibrosis
Acute kidney injury is another important trigger that many people overlook. A sudden insult to the kidneys, whether from a severe infection, a drug reaction, or a surgical complication, does not always resolve cleanly. If repair goes wrong, persistent inflammation and matrix buildup can set the stage for chronic kidney disease.10PubMed Central. Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease Transition The transition from acute injury to chronic disease involves many of the same pathways seen in diabetes and hypertension: cell death, ongoing inflammation, and matrix deposition that never shuts off.11PubMed. Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers
Other causes include autoimmune kidney diseases (like lupus nephritis and IgA nephropathy), polycystic kidney disease, chronic urinary tract obstruction, and certain medications. Regardless of the starting point, the downstream scarring process converges on a remarkably similar set of molecular signals.
The Central Role of TGF-β
If kidney fibrosis has a master switch, it is a signaling molecule called transforming growth factor-beta (TGF-β). TGF-β ramps up the production of matrix proteins, blocks the enzymes that would normally break those proteins down, and alters how kidney cells interact with one another.12PubMed Central. Targeting TGF-β Signaling in Kidney Fibrosis It is so central that most experimental anti-fibrotic strategies have tried to block it in one way or another. The challenge is that TGF-β also has protective roles in the kidney, including keeping inflammation in check and supporting tissue repair after acute injuries.13PubMed Central. TGF-β signaling in the kidney: profibrotic and protective effects Shutting it down entirely would be like pulling a fire alarm’s wires to stop a false alarm: you solve one problem and create a new, potentially worse one. That dual nature is a big reason why drugs aimed directly at TGF-β have struggled in clinical trials.
Inflammation, Macrophages, and the Immune Angle
Fibrosis does not happen in a sterile, mechanical way. The immune system is deeply involved, and macrophages (the immune cells that act as both first responders and cleanup crews) play an outsized role. In healthy kidneys, macrophages are present in modest numbers. In diseased kidneys, their numbers spike dramatically, and their behavior shifts depending on the signals around them.14PubMed. Macrophages in kidney injury, inflammation, and fibrosis
Some macrophages adopt a pro-inflammatory stance that helps clear infection or damaged cells but also inflicts collateral damage on healthy tissue. Others shift into an anti-inflammatory, repair-oriented mode. In principle, the repair-oriented macrophages should help resolve injury. In practice, a specific subset of these repair-type macrophages is strongly associated with fibrosis in both human and experimental kidney disease.15Nature Reviews Nephrology. Macrophages: versatile players in renal inflammation and fibrosis There is even evidence that bone marrow-derived macrophages can transform directly into myofibroblasts within the injured kidney, a process driven by TGF-β signaling. This macrophage-to-myofibroblast transition may be a key checkpoint where chronic inflammation crosses over into permanent scarring.
The Oxygen Starvation Cycle
One of the more insidious aspects of kidney fibrosis is how it creates its own worsening environment through oxygen deprivation. Healthy kidney tissue depends on a dense network of tiny blood vessels called peritubular capillaries. As fibrosis progresses, pericytes detach from those capillaries and convert into scar-producing myofibroblasts, compromising the vessels they were meant to support.16Kidney International Supplements. Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes This loss of capillaries, sometimes called capillary rarefaction, means less blood flow and less oxygen reaching the kidney’s working cells.
Imaging studies of fibrotic kidneys confirm this: as the degree of fibrosis increases, the density of intact capillaries drops.17Scientific Reports. Identifying key genes related to the peritubular capillary rarefaction in renal interstitial fibrosis by bioinformatics At the same time, the expanding scar tissue physically pushes capillaries farther away from the tubular cells that need oxygen. In animal models of kidney fibrosis, the diffusion distance from capillaries to the nearest tubule increased by over 100 percent, making the kidney cortex highly vulnerable to oxygen starvation.18PubMed Central. Alterations to peritubular capillary structure in a rat model of kidney interstitial fibrosis: Implications for oxygen diffusion Low oxygen then triggers further fibrotic signaling, and the cycle feeds itself.
Why Symptoms Come Late
Kidney fibrosis itself does not produce unique symptoms. It is the loss of kidney function that symptoms reflect, and the kidneys have substantial reserve capacity. You can lose a significant fraction of your filtering ability before anything feels wrong. Early-stage chronic kidney disease is often completely silent, detected only through routine blood tests (an elevated creatinine or a falling estimated glomerular filtration rate) or urine tests showing protein leakage.
As fibrosis advances and function drops further, symptoms gradually appear:
- Fatigue: less efficient waste removal and declining red blood cell production (the kidneys make erythropoietin) leave you drained.
- Swelling: fluid and sodium that the kidneys can no longer handle accumulate in the legs, ankles, or around the eyes.
- Changes in urination: you may produce more urine at night, or less urine overall as disease progresses.
- Nausea and appetite loss: waste products building up in the blood (uremia) cause a general feeling of sickness.
- Itching: mineral imbalances and toxin buildup can cause persistent, hard-to-treat skin itching.
By the time these symptoms are obvious, fibrosis is usually advanced. That reality underscores why screening matters for anyone with diabetes, hypertension, or a history of acute kidney injury.
Diagnosing Fibrosis Without Surgery
The gold standard for confirming kidney fibrosis has traditionally been a needle biopsy, where a small core of tissue is examined under a microscope. Biopsies give direct information about the amount and pattern of scarring, but they carry risks (bleeding, infection) and sample only a tiny sliver of an organ that may scar unevenly. That limitation has driven a push toward non-invasive alternatives.
Standard blood and urine markers of kidney function (creatinine, albumin-to-creatinine ratio) tell you the kidney is struggling but do not specifically measure fibrosis. Existing markers of chronic kidney disease do not fully or specifically reflect the degree of scarring.19BioMed Central / Fibrogenesis & Tissue Repair. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? One promising avenue involves identifying fragments of matrix proteins in blood or urine that are generated when specific enzymes chop up collagen and other scar components. These “neo-epitope” biomarkers could one day provide a direct readout of fibrotic activity, though most remain in the research phase.
Imaging is advancing rapidly. MRI-based techniques can now detect two hallmarks of fibrosis: the loss of capillaries and the stiffening of kidney tissue.20PubMed Central. Could MRI Be Used To Image Kidney Fibrosis? A Review of Recent Advances and Remaining Barriers Diffusion MRI tracks how freely water moves through tissue (scar restricts it), while blood oxygenation level-dependent MRI picks up the oxygen deficit caused by capillary loss. Ultrasound and MRI elastography measure how stiff the kidney has become, since fibrotic tissue resists deformation more than healthy tissue.21PubMed Central. Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques These tools are not yet standard in everyday clinical practice, but the findings in both animal and human studies have been encouraging enough to suggest they could eventually reduce the need for biopsies.22PubMed Central. Advances in imaging techniques to assess kidney fibrosis
Current Treatment Options
No drug on the market today can reliably reverse established kidney fibrosis. Current therapy focuses on slowing the process by managing the upstream causes and blocking the pathways that feed into scarring.
The backbone of treatment for most patients is drugs that block the RAAS. ACE inhibitors and angiotensin receptor blockers (ARBs) lower blood pressure, reduce proteinuria, and have direct anti-fibrotic effects by dampening the angiotensin II signaling that drives matrix production.23PubMed Central. Renal interstitial fibrosis and Angiotensin inhibition These drugs are well-established as first-line therapy for diabetic and hypertensive kidney disease. There is some evidence that ACE inhibitors may offer stronger anti-fibrotic effects than ARBs through additional mechanisms beyond blood pressure lowering, though comparative data remain limited.24PubMed Central. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
A newer addition to the toolkit is finerenone, a non-steroidal mineralocorticoid receptor antagonist. In animal models of kidney fibrosis, finerenone reduced myofibroblast accumulation by about 31 percent and collagen deposition by about 34 percent, effects that appeared independent of blood pressure changes.25American Journal of Nephrology. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis Clinical trials in people with diabetic kidney disease have shown kidney and cardiovascular benefits, and finerenone is now approved for use in that population. Interestingly, empagliflozin (an SGLT2 inhibitor known for its kidney-protective effects in other contexts) showed essentially no anti-fibrotic effect in the same animal model, with collagen levels barely changing. SGLT2 inhibitors still protect kidneys through other mechanisms such as reducing hyperfiltration and inflammation, but the fibrosis angle specifically may not be their strength.
Beyond medications, aggressive management of blood sugar in diabetic patients, blood pressure control, dietary sodium restriction, and avoiding nephrotoxic drugs (like chronic high-dose NSAIDs) all help slow the march toward end-stage disease. None of these interventions undo scar that is already in place, but they can significantly slow the rate at which new scar accumulates.
Experimental and Emerging Therapies
The biggest unmet need in nephrology is a drug that can halt or reverse fibrosis directly. Several approaches are being explored, though none has crossed the finish line yet.
Because TGF-β sits at the center of fibrotic signaling, it has been a natural drug target. Anti-TGF-β antibodies such as fresolimumab and LY2382770 were tested in patients with focal segmental glomerulosclerosis and diabetic kidney disease, respectively, but neither demonstrated clear efficacy.26Signal Transduction and Targeted Therapy. Kidney fibrosis: from mechanisms to therapeutic medicines Pirfenidone, a small molecule that suppresses TGF-β and is already approved for lung fibrosis, has shown some ability to stabilize kidney function in patients with diabetic kidney disease and focal segmental glomerulosclerosis. An antibody targeting connective tissue growth factor (CTGF), a downstream effector of TGF-β, was well tolerated and reduced protein leakage in an early-phase trial in diabetic kidney disease patients.
Stem cell therapy is another area of active research. Preclinical studies suggest that mesenchymal stem cells from various tissue sources can reduce matrix accumulation and improve kidney function in animal models of fibrosis.27PubMed Central. Stem cells in the treatment of renal fibrosis: a review of preclinical and clinical studies of renal fibrosis pathogenesis The proposed mechanisms include dampening inflammation, shifting macrophage behavior away from the pro-fibrotic state, and secreting growth factors that support tissue repair. Early clinical applications have been reported, but the field is still working through questions of optimal cell source, dosing, and long-term safety.28PubMed Central. Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy
Epigenetic approaches represent a newer frontier. Fibrotic kidneys show sweeping changes in how genes are switched on and off, involving alterations to DNA methylation patterns, histone modifications, and networks of non-coding RNA molecules.29PubMed Central. Epigenetic strategies for mitigating kidney fibrosis Drugs that target these epigenetic switches could theoretically reprogram fibrotic cells back toward a healthier state, but this work is still largely in the laboratory.
The Gut-Kidney Connection
An area gaining attention is the role of the gut in kidney fibrosis. As kidney function declines, waste products that would normally be excreted start to accumulate, and some of those wastes are actually produced by gut bacteria. In people with chronic kidney disease, the gut microbiome shifts: beneficial bacteria that produce helpful compounds like butyrate decline, while species that generate protein-derived toxins increase.30Frontiers in Immunology. The gut-kidney axis in chronic kidney disease: a vicious cycle of microbial dysbiosis and uremic toxin accumulation
The toxins generated by this altered microbiome, including indoxyl sulfate and p-cresyl sulfate, are not easily removed by dialysis and accumulate as kidney function falls. They damage the intestinal lining, allowing bacterial products to leak into the bloodstream and triggering inflammation that reaches back to the kidneys.31PubMed Central. The Impact of CKD on Uremic Toxins and Gut Microbiota Evidence supports a role for these gut-derived toxins in promoting kidney fibrosis, vascular calcification, and other complications of chronic kidney disease through inflammatory, oxidative, and cell-death pathways.32PubMed. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins This creates a vicious cycle: failing kidneys change the gut environment, the changed gut produces more harmful toxins, and those toxins accelerate kidney damage.
Whether manipulating the gut microbiome (through diet, prebiotics, probiotics, or targeted adsorbents that bind uremic toxins in the intestine) can meaningfully slow kidney fibrosis in people remains an open question. The biology is compelling, and clinical trials are underway, but firm answers are still forthcoming. In the meantime, dietary strategies that reduce protein fermentation in the colon, such as increasing fiber intake and moderating protein consumption under medical guidance, align with general nutritional recommendations for people with chronic kidney disease and could plausibly help on the gut-kidney front as well.
When Kidneys Are Young or Old
Fibrosis does not follow the same script at every age. In children, the most common triggers differ from those in adults. Congenital abnormalities of the kidneys and urinary tract, childhood glomerular diseases, and complications from premature birth are leading causes. Pediatric kidneys have a greater capacity for growth and repair, which can sometimes counterbalance early fibrotic changes, but severe or recurring injuries can still set a child on a trajectory toward chronic kidney disease that plays out over decades.
At the other end of life, aging kidneys become more vulnerable to fibrosis even without an obvious disease trigger. Kidney tissue from elderly individuals often shows low-grade scarring and a reduced density of functioning nephrons compared with younger adults. Cellular senescence, the process by which aging cells stop dividing but remain metabolically active and secrete inflammatory signals, is increasingly recognized as a contributor to kidney fibrosis in the aging population. Senescent cells accumulate in the kidney over time and create a local environment that encourages matrix deposition. Experimental drugs called senolytics, which selectively eliminate senescent cells, have shown promise in animal models of kidney aging, though human trials remain early-stage.
For older adults, even a relatively mild acute kidney injury (from dehydration, a contrast dye used in imaging, or a bout of infection) carries an elevated risk of incomplete recovery and transition to chronic fibrosis. That risk is compounded by the fact that older kidneys start with fewer functional units and less physiological cushion. Clinicians are increasingly aware of this vulnerability, which is why careful medication management and hydration strategies around procedures become especially important in older patients.